Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the closing of its underwritten public offering of 8,581,250 shares of its common stock, and to certain investors that so choose, pre-funded warrants to purchase 2,200,000 shares of its common stock at an exercise price of $0.0001 per share. The shares of common stock sold inclu ...